


PRODUCT INFORMATION



Tasisulam

Item No. 21556

CAS Registry No.: 519055-62-0
Formal Name: N-[(5-bromo-2-thienyl)sulfonyl]-
2,4-dichloro-benzamide
Synonym: LY573636
MF: C₁₁H₆BrCl₂NO₃S₂
FW: 415.1
Purity: ≥98%
UV/Vis.: λ_{max}: 205, 231, 268 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tasisulam is supplied as a crystalline solid. A stock solution may be made by dissolving the tasisulam in the solvent of choice, which should be purged with an inert gas. Tasisulam is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of tasisulam in ethanol is approximately 10 mg/ml and approximately 20 mg/ml in DMSO and DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of tasisulam can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of tasisulam in PBS, pH 7.2, is approximately 0.2 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Tasisulam is an anticancer agent that inhibits the growth of Calu-6 non-small cell lung carcinoma (NSCLC) and A-375 melanoma cell lines (EC₅₀s = 10 and 25 μM, respectively).¹ It arrests the cell cycle at the G₂/M phase and induces apoptosis of Calu-6 cells in a concentration-dependent manner. Tasisulam induces non-apoptotic growth arrest in human vascular endothelial cells (HUVECs) and inhibits VEGF-, FGF-, and EGF-induced endothelial cord formation *in vitro* (EC₅₀s = 47, 103, and 34 nM, respectively). *In vivo*, tasisulam (25 and 50 mg/kg) reduces hemoglobin content and blood vessel density in a Matrigel™ plug model of neoangiogenesis. It also reduces tumor growth in a dose-dependent manner in a Calu-6 mouse xenograft model *via* arrest of the cell cycle at the G₂/M phase, induction of apoptosis, and reduction of tumor blood vessel density. Formulations containing tasisulam are under clinical investigation for the treatment of advanced solid tumors.

Reference

1. Meier, T., Uhlik, M., Chintharlapalli, S., *et al.* Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. *Mol. Cancer Ther.* **10(11)**, 2168-2178 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM